- Home
- ROIV
as of 12-12-2025 3:41pm EST
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
| Founded: | 2014 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 14.1B | IPO Year: | N/A |
| Target Price: | $21.94 | AVG Volume (30 days): | 6.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.73 - $22.45 | Next Earning Date: | 11-10-2025 |
| Revenue: | $20,329,000 | Revenue Growth: | -45.13% |
| Revenue Growth (this year): | -29.6% | Revenue Growth (next year): | 376.94% |
AI-Powered ROIV Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Roivant Sciences Ltd. (ROIV)
President & Immunovant CEO
Avg Cost/Share
$20.85
Shares
200,000
Total Value
$4,170,000.00
Owned After
1,497,908
SEC Form 4
10% Owner
Avg Cost/Share
$20.51
Shares
539,650
Total Value
$11,068,221.50
Owned After
33,653,756
SEC Form 4
10% Owner
Avg Cost/Share
$20.33
Shares
1,027,670
Total Value
$20,892,531.10
Owned After
33,653,756
SEC Form 4
10% Owner
Avg Cost/Share
$20.81
Shares
287,283
Total Value
$5,978,359.23
Owned After
33,653,756
SEC Form 4
President & Immunovant CEO
Avg Cost/Share
$16.25
Shares
20,727
Total Value
$336,813.75
Owned After
1,497,908
SEC Form 4
President & Immunovant CEO
Avg Cost/Share
$16.30
Shares
104,940
Total Value
$1,710,522.00
Owned After
1,497,908
SEC Form 4
President & Immunovant CEO
Avg Cost/Share
$16.20
Shares
138,602
Total Value
$2,245,352.40
Owned After
1,497,908
SEC Form 4
President & Immunovant CEO
Avg Cost/Share
$16.15
Shares
355,161
Total Value
$5,735,850.15
Owned After
1,497,908
SEC Form 4
President & Immunovant CEO
Avg Cost/Share
$16.34
Shares
171,396
Total Value
$2,800,610.64
Owned After
1,497,908
SEC Form 4
President & Immunovant CEO
Avg Cost/Share
$14.83
Shares
611,000
Total Value
$9,061,130.00
Owned After
1,497,908
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Venker Eric | ROIV | President & Immunovant CEO | Dec 9, 2025 | Sell | $20.85 | 200,000 | $4,170,000.00 | 1,497,908 | |
| Ramaswamy Vivek | ROIV | 10% Owner | Nov 17, 2025 | Sell | $20.51 | 539,650 | $11,068,221.50 | 33,653,756 | |
| Ramaswamy Vivek | ROIV | 10% Owner | Nov 14, 2025 | Sell | $20.33 | 1,027,670 | $20,892,531.10 | 33,653,756 | |
| Ramaswamy Vivek | ROIV | 10% Owner | Nov 13, 2025 | Sell | $20.81 | 287,283 | $5,978,359.23 | 33,653,756 | |
| Venker Eric | ROIV | President & Immunovant CEO | Oct 13, 2025 | Sell | $16.25 | 20,727 | $336,813.75 | 1,497,908 | |
| Venker Eric | ROIV | President & Immunovant CEO | Oct 9, 2025 | Sell | $16.30 | 104,940 | $1,710,522.00 | 1,497,908 | |
| Venker Eric | ROIV | President & Immunovant CEO | Oct 8, 2025 | Sell | $16.20 | 138,602 | $2,245,352.40 | 1,497,908 | |
| Venker Eric | ROIV | President & Immunovant CEO | Oct 7, 2025 | Sell | $16.15 | 355,161 | $5,735,850.15 | 1,497,908 | |
| Venker Eric | ROIV | President & Immunovant CEO | Oct 6, 2025 | Sell | $16.34 | 171,396 | $2,800,610.64 | 1,497,908 | |
| Venker Eric | ROIV | President & Immunovant CEO | Sep 23, 2025 | Sell | $14.83 | 611,000 | $9,061,130.00 | 1,497,908 |
Compare ROIV vs Leading Stocks
See how ROIV stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ROIV Roivant Sciences Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.